← All trials
NCT05712616
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Feb 3, 2023
- Last posted
- Feb 3, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aga Khan UniversityLead sponsor
- Aga Khan UniversityReponsible party - principal investigator
- Aga Khan UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.